Global Radiopharmaceuticals in Nuclear Medicine Market Research Report 2021
- Published Date: 2021-04-20
- Report ID: 103190
- Pages: 180
-
Format:
Prudent Markets Predicts that Radiopharmaceuticals in Nuclear Medicine Market was valued USD xxxx unit in 2020 and is expected to reach USD xxxx Unit by the year 2025, growing at a CAGR of xx% globally.
Global Radiopharmaceuticals in Nuclear Medicine Market Overview:
Global Radiopharmaceuticals in Nuclear Medicine Market Report 2020 comes with the extensive industry analysis of development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2020-2025.This research study of Radiopharmaceuticals in Nuclear Medicine involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Impact of COVID-19 on Radiopharmaceuticals in Nuclear Medicine Market
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affected the Radiopharmaceuticals in Nuclear Medicine market in 2020.
Global Radiopharmaceuticals in Nuclear Medicine Market Segmentation
By Type, Radiopharmaceuticals in Nuclear Medicine market has been segmented into:
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
By Application, Radiopharmaceuticals in Nuclear Medicine market has been segmented into:
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
Asia-Pacific (China, India, Japan, Southeast Asia etc.)
South America (Brazil, Argentina etc.)
Middle East & Africa (Saudi Arabia, South Africa etc.)
Top Key Players Covered in Radiopharmaceuticals in Nuclear Medicine market are:
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories Inc.
Cardinal Health Inc.
Covidien
Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec Inc. (Sigma-Aldrich)
Lantheus Medical Imaging Inc.
Nordion Inc.
Ntp Radioisotopes (Pty) Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries Ltd. Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co. Ltd.
Institute Of Radioelement (IRE)
1. Market Overview of Radiopharmaceuticals in Nuclear Medicine
1.1 Radiopharmaceuticals in Nuclear Medicine Market Overview
1.1.1 Radiopharmaceuticals in Nuclear Medicine Product Scope
1.1.2 Market Status and Outlook
1.2 Radiopharmaceuticals in Nuclear Medicine Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Radiopharmaceuticals in Nuclear Medicine Historic Market Size by Regions (2015-2020)
1.4 Radiopharmaceuticals in Nuclear Medicine Forecasted Market Size by Regions (2021-2026)
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth (2015-2026)
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Radiopharmaceuticals in Nuclear Medicine Sales Market by Type (2015-2026)
2.1 Global Radiopharmaceuticals in Nuclear Medicine Historic Market Size by Type (2015-2020)
2.2 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Market Size by Type (2021-2026)
2.3 Diagnostic Radiopharmaceuticals
2.4 Therapy Radiopharmaceuticals
2.5 Enriched Stable Isotopes
3. Covid-19 Impact Radiopharmaceuticals in Nuclear Medicine Sales Market by Application (2015-2026)
3.1 Global Radiopharmaceuticals in Nuclear Medicine Historic Market Size by Application (2015-2020)
3.2 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Market Size by Application (2021-2026)
3.3 Diagnostic Application
3.4 Therapeutic Application
3.5 Research
3.6 Pharmaceutical
3.7 Others
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Radiopharmaceuticals in Nuclear Medicine Production Capacity Market Share by Manufacturers (2015-2020)
4.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Manufacturers (2015-2020)
4.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Manufacturers (2015-2020)
5. Company Profiles and Key Figures in Radiopharmaceuticals in Nuclear Medicine Business
5.1 Bracco Imaging S.P.A.
5.1.1 Bracco Imaging S.P.A. Company Profile
5.1.2 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Specification
5.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.2 Cambridge Isotope Laboratories Inc.
5.2.1 Cambridge Isotope Laboratories Inc. Company Profile
5.2.2 Cambridge Isotope Laboratories Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
5.2.3 Cambridge Isotope Laboratories Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.3 Cardinal Health Inc.
5.3.1 Cardinal Health Inc. Company Profile
5.3.2 Cardinal Health Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
5.3.3 Cardinal Health Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.4 Covidien
5.4.1 Covidien Company Profile
5.4.2 Covidien Radiopharmaceuticals in Nuclear Medicine Product Specification
5.4.3 Covidien Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.5 Plc
5.5.1 Plc Company Profile
5.5.2 Plc Radiopharmaceuticals in Nuclear Medicine Product Specification
5.5.3 Plc Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.6 Eczacibasi-Monrol
5.6.1 Eczacibasi-Monrol Company Profile
5.6.2 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Specification
5.6.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.7 Fujifilm Holdings Corporation
5.7.1 Fujifilm Holdings Corporation Company Profile
5.7.2 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Specification
5.7.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.8 GE Healthcare (Subsidiary Of General Electric Company)
5.8.1 GE Healthcare (Subsidiary Of General Electric Company) Company Profile
5.8.2 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Specification
5.8.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.9 IBA Group
5.9.1 IBA Group Company Profile
5.9.2 IBA Group Radiopharmaceuticals in Nuclear Medicine Product Specification
5.9.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.10 Isotec Inc. (Sigma-Aldrich)
5.10.1 Isotec Inc. (Sigma-Aldrich) Company Profile
5.10.2 Isotec Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Specification
5.10.3 Isotec Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.11 Lantheus Medical Imaging Inc.
5.11.1 Lantheus Medical Imaging Inc. Company Profile
5.11.2 Lantheus Medical Imaging Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
5.11.3 Lantheus Medical Imaging Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.12 Nordion Inc.
5.12.1 Nordion Inc. Company Profile
5.12.2 Nordion Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
5.12.3 Nordion Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.13 Ntp Radioisotopes (Pty) Ltd.
5.13.1 Ntp Radioisotopes (Pty) Ltd. Company Profile
5.13.2 Ntp Radioisotopes (Pty) Ltd. Radiopharmaceuticals in Nuclear Medicine Product Specification
5.13.3 Ntp Radioisotopes (Pty) Ltd. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.14 Siemens Healthcare (Subsidiary Of Siemens AG)
5.14.1 Siemens Healthcare (Subsidiary Of Siemens AG) Company Profile
5.14.2 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Specification
5.14.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.15 Taiyo Nippon Sanso Corporation
5.15.1 Taiyo Nippon Sanso Corporation Company Profile
5.15.2 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Specification
5.15.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.16 Urenco Limited
5.16.1 Urenco Limited Company Profile
5.16.2 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Specification
5.16.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.17 Rotem Industries Ltd. Inc.
5.17.1 Rotem Industries Ltd. Inc. Company Profile
5.17.2 Rotem Industries Ltd. Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
5.17.3 Rotem Industries Ltd. Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.18 Australian Nuclear Association And Technology Organization (ANSTO)
5.18.1 Australian Nuclear Association And Technology Organization (ANSTO) Company Profile
5.18.2 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Specification
5.18.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.19 Board of Radiation And Isotope Technology (BRIT)
5.19.1 Board of Radiation And Isotope Technology (BRIT) Company Profile
5.19.2 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Specification
5.19.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.20 Institute of Atomic Energy Polatom Radioisotope Centre
5.20.1 Institute of Atomic Energy Polatom Radioisotope Centre Company Profile
5.20.2 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Specification
5.20.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.21 Institute of Isotopes Co. Ltd.
5.21.1 Institute of Isotopes Co. Ltd. Company Profile
5.21.2 Institute of Isotopes Co. Ltd. Radiopharmaceuticals in Nuclear Medicine Product Specification
5.21.3 Institute of Isotopes Co. Ltd. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.22 Institute Of Radioelement (IRE)
5.22.1 Institute Of Radioelement (IRE) Company Profile
5.22.2 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Specification
5.22.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2015-2020)
6. North America
6.1 North America Radiopharmaceuticals in Nuclear Medicine Market Size (2015-2026)
6.2 North America Radiopharmaceuticals in Nuclear Medicine Key Players in North America (2015-2020)
6.3 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Type (2015-2020)
6.4 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Application (2015-2020)
7. East Asia
7.1 East Asia Radiopharmaceuticals in Nuclear Medicine Market Size (2015-2026)
7.2 East Asia Radiopharmaceuticals in Nuclear Medicine Key Players in North America (2015-2020)
7.3 East Asia Radiopharmaceuticals in Nuclear Medicine Market Size by Type (2015-2020)
7.4 East Asia Radiopharmaceuticals in Nuclear Medicine Market Size by Application (2015-2020)
8. Europe
8.1 Europe Radiopharmaceuticals in Nuclear Medicine Market Size (2015-2026)
8.2 Europe Radiopharmaceuticals in Nuclear Medicine Key Players in North America (2015-2020)
8.3 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Type (2015-2020)
8.4 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Application (2015-2020)
9. South Asia
9.1 South Asia Radiopharmaceuticals in Nuclear Medicine Market Size (2015-2026)
9.2 South Asia Radiopharmaceuticals in Nuclear Medicine Key Players in North America (2015-2020)
9.3 South Asia Radiopharmaceuticals in Nuclear Medicine Market Size by Type (2015-2020)
9.4 South Asia Radiopharmaceuticals in Nuclear Medicine Market Size by Application (2015-2020)
10. Southeast Asia
10.1 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Market Size (2015-2026)
10.2 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Key Players in North America (2015-2020)
10.3 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Market Size by Type (2015-2020)
10.4 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Market Size by Application (2015-2020)
11. Middle East
11.1 Middle East Radiopharmaceuticals in Nuclear Medicine Market Size (2015-2026)
11.2 Middle East Radiopharmaceuticals in Nuclear Medicine Key Players in North America (2015-2020)
11.3 Middle East Radiopharmaceuticals in Nuclear Medicine Market Size by Type (2015-2020)
11.4 Middle East Radiopharmaceuticals in Nuclear Medicine Market Size by Application (2015-2020)
12. Africa
12.1 Africa Radiopharmaceuticals in Nuclear Medicine Market Size (2015-2026)
12.2 Africa Radiopharmaceuticals in Nuclear Medicine Key Players in North America (2015-2020)
12.3 Africa Radiopharmaceuticals in Nuclear Medicine Market Size by Type (2015-2020)
12.4 Africa Radiopharmaceuticals in Nuclear Medicine Market Size by Application (2015-2020)
13. Oceania
13.1 Oceania Radiopharmaceuticals in Nuclear Medicine Market Size (2015-2026)
13.2 Oceania Radiopharmaceuticals in Nuclear Medicine Key Players in North America (2015-2020)
13.3 Oceania Radiopharmaceuticals in Nuclear Medicine Market Size by Type (2015-2020)
13.4 Oceania Radiopharmaceuticals in Nuclear Medicine Market Size by Application (2015-2020)
14. South America
14.1 South America Radiopharmaceuticals in Nuclear Medicine Market Size (2015-2026)
14.2 South America Radiopharmaceuticals in Nuclear Medicine Key Players in North America (2015-2020)
14.3 South America Radiopharmaceuticals in Nuclear Medicine Market Size by Type (2015-2020)
14.4 South America Radiopharmaceuticals in Nuclear Medicine Market Size by Application (2015-2020)
15. Rest of the World
15.1 Rest of the World Radiopharmaceuticals in Nuclear Medicine Market Size (2015-2026)
15.2 Rest of the World Radiopharmaceuticals in Nuclear Medicine Key Players in North America (2015-2020)
15.3 Rest of the World Radiopharmaceuticals in Nuclear Medicine Market Size by Type (2015-2020)
15.4 Rest of the World Radiopharmaceuticals in Nuclear Medicine Market Size by Application (2015-2020)
16 Radiopharmaceuticals in Nuclear Medicine Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porters Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
